The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions-Reference-Cited by-同舟云学术

The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions

Published:2020-10-01 Issue:19 Volume:59 Page:2343-2351
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kambayashi Harutaka¹,Omori Teppei¹,Saito Satomi¹,Murasugi Shun¹,Kashiwagi Hiroyuki¹,Ito Ayumi¹,Yonezawa Maria¹,Nakamura Shinichi¹,Tokushige Katsutoshi¹

Affiliation:

1. Institute of Gastroenterology, Tokyo Women's Medical University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/19/59_5000-20/_pdf

Reference30 articles.

1. 1. Hashimoto T. Behcet's disease. J Jpn Soc Intern Med 91: 94-98, 2012.

2. 2. Ishigatsubo Y, Samukawa S. Behcet's disease from the aspect of autoinflammatory disease. Jpn J Clin Immunol 34: 408-419, 2011.

3. 3. Saadoun D, Wechsler B. Behçet's disease. Orphanet J Rare Dis 7: 20, 2012.

4. 4. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 3: e297, 2006.

5. 5. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 42: 698-702, 2010.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Developments in the Prevention and Improvement of Intestinal Disorders: A Mini-Review;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-05-17

2. Entero-Behcet: A Challenging Aspect of Behcet Disease;Rare Diseases - Recent Advances [Working Title];2022-05-31

3. The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis;Journal of Gastroenterology and Hepatology;2022-01-03

4. Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis;Therapeutic Advances in Gastroenterology;2022-01

5. Infliximab;Reactions Weekly;2020-12